197 related articles for article (PubMed ID: 35147178)
1. Erdafitinib for locally advanced or metastatic urothelial carcinoma.
Siefker-Radtke AO; Loriot Y
Am J Health Syst Pharm; 2022 May; 79(11):824-825. PubMed ID: 35147178
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
[TBL] [Abstract][Full Text] [Related]
3. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
[TBL] [Abstract][Full Text] [Related]
4. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
Franza A; Pirovano M; Giannatempo P; Cosmai L
Future Oncol; 2022 Jun; 18(19):2455-2464. PubMed ID: 35387485
[TBL] [Abstract][Full Text] [Related]
5. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
[TBL] [Abstract][Full Text] [Related]
6. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Roubal K; Myint ZW; Kolesar JM
Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
[TBL] [Abstract][Full Text] [Related]
7. Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K; Bellmunt J
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
[No Abstract] [Full Text] [Related]
8. Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Dosne AG; Valade E; Goeyvaerts N; De Porre P; Avadhani A; O'Hagan A; Li LY; Ouellet D; Perez Ruixo JJ
Cancer Chemother Pharmacol; 2022 Feb; 89(2):151-164. PubMed ID: 34977972
[TBL] [Abstract][Full Text] [Related]
9. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Tilgener C; Bedke J
Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
[No Abstract] [Full Text] [Related]
10. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
[TBL] [Abstract][Full Text] [Related]
11. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
Loriot Y; O'Hagan A; Siefker-Radtke AO
Future Oncol; 2024 Feb; 20(5):231-243. PubMed ID: 37916514
[TBL] [Abstract][Full Text] [Related]
12. Erdafitinib (Balversa) for urothelial carcinoma.
Med Lett Drugs Ther; 2024 May; 66(1702):e83-e84. PubMed ID: 38696316
[No Abstract] [Full Text] [Related]
13. Fibroblast growth factor receptors across urothelial carcinoma landscape.
Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
[TBL] [Abstract][Full Text] [Related]
14. Erdafitinib exerts the anticancer effect on urothelial carcinoma
Jin YY; Tong SQ; Tong M
Pharmazie; 2020 May; 75(5):195-197. PubMed ID: 32393427
[TBL] [Abstract][Full Text] [Related]
15. [High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].
Grülllich C
Urologe A; 2020 Apr; 59(4):478-479. PubMed ID: 32103289
[No Abstract] [Full Text] [Related]
16. Erdafitinib: First Global Approval.
Markham A
Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
[TBL] [Abstract][Full Text] [Related]
17. Erdafitinib for advanced urothelial carcinoma.
Burki TK
Lancet Oncol; 2019 Sep; 20(9):e469. PubMed ID: 31378458
[No Abstract] [Full Text] [Related]
18. FGFR alterations in urothelial carcinoma: Picking the right target.
Hubert P; Selmani Z; Loriot Y; Thiery-Vuillemin A
Bull Cancer; 2021 Jun; 108(6):566-570. PubMed ID: 34020787
[No Abstract] [Full Text] [Related]
19. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
Peng J; Sridhar S; Siefker-Radtke AO; Selvarajah S; Jiang DM
Curr Treat Options Oncol; 2022 Sep; 23(9):1269-1287. PubMed ID: 35962938
[TBL] [Abstract][Full Text] [Related]
20. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Qin Q; Patel V; Galsky MD
Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]